MRZM Stock Analysis
MR
Uncovered
Marizyme Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Marizyme, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of therapies that minimize mortality and costs in the acute care space. The company is headquartered in Jupiter, Florida and currently employs 11 full-time employees. The firm is engaged in the research, manufacture and commercialization of medical devices, diagnostics and products to address unmet clinical needs. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.